{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T14:59:55Z","timestamp":1648825195888},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1016\/j.bbrc.2010.03.095","type":"journal-article","created":{"date-parts":[[2010,5,22]],"date-time":"2010-05-22T04:48:07Z","timestamp":1274503687000},"page":"131-134","source":"Crossref","is-referenced-by-count":0,"title":["Molecular aspects in clinical hemostasis research at Karolinska Institutet"],"prefix":"10.1016","volume":"396","author":[{"given":"Margareta","family":"Blomb\u00e4ck","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2010.03.095_bib1","first-page":"263","article-title":"Erik Jorpes \u2013 a pragmatic physiological clinical chemist. Selected papers in the history of biochemistry: personal recollections","volume":"4","author":"Mutt","year":"2000","journal-title":"Compr. Biochem."},{"key":"10.1016\/j.bbrc.2010.03.095_bib2","unstructured":"M. Blomb\u00e4ck, Blood coagulation research at Karolinska Institutet 1920\u20132004: Pt. I \u2013 Basic research and Pt. II \u2013 Clinical Research, Karolinska Institutet, Stockholm, 2008. Available from: <http:\/\/ki.se\/ki\/jsp\/polopoly\/>."},{"key":"10.1016\/j.bbrc.2010.03.095_bib3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3109\/10731198309118804","article-title":"A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue","volume":"11","author":"Larm","year":"1983","journal-title":"Biomater. Med. Devices Artif. Organs"},{"key":"10.1016\/j.bbrc.2010.03.095_bib4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0069-8032(07)45006-9","article-title":"A journey with bleeding time factor","volume":"45","author":"Blomb\u00e4ck","year":"2007","journal-title":"Compr. Biochem."},{"issue":"Suppl. 2","key":"10.1016\/j.bbrc.2010.03.095_bib5","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1046\/j.1365-2516.1999.0050s2012.x","article-title":"Scientific visits to the \u00c5land islands","volume":"5","author":"Blomb\u00e4ck","year":"1999","journal-title":"Haemophilia"},{"key":"10.1016\/j.bbrc.2010.03.095_bib6","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1111\/j.1538-7836.2006.02056.x","article-title":"Travels with fibrinogen","volume":"4","author":"Blomb\u00e4ck","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.bbrc.2010.03.095_bib7","first-page":"59","article-title":"Synthetic peptides with anticoagulant and vasodilating activity","volume":"107","author":"Blomb\u00e4ck","year":"1969","journal-title":"Scand. Clin. Lab. Invest. Suppl."},{"key":"10.1016\/j.bbrc.2010.03.095_bib8","first-page":"446","article-title":"Substrates for determination of trypsin, thrombin and thrombin-like enzymes","volume":"98","author":"Svendsen","year":"1972","journal-title":"Folia Haematol. Int. Mag. Klin. Morphol. Blutforsch."},{"key":"10.1016\/j.bbrc.2010.03.095_bib9","first-page":"85","article-title":"Studies on assays for plasma prekallikrein and for the monitoring of coumarol therapy","volume":"7","author":"Egberg","year":"1978","journal-title":"Haemostasis"},{"key":"10.1016\/j.bbrc.2010.03.095_bib10","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/0049-3848(78)90324-9","article-title":"Determination of vitamin K sensitive coagulation factors in plasma: studies on three methods using synthetic chromogenic substrates","volume":"12","author":"Bergstr\u00f6m","year":"1978","journal-title":"Thromb. Res."},{"key":"10.1016\/j.bbrc.2010.03.095_bib11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/00001721-200501000-00010","article-title":"Modifications of flow measurement to determine fibrin gel permeability and the preliminary use in research and clinical materials","volume":"16","author":"He","year":"2005","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.bbrc.2010.03.095_bib12","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1055\/s-0038-1656337","article-title":"Fibrin gel network characteristics and coronary heart disease: relations to fibrinogen concentration, acute phase protein, serum lipoproteins and coronary atherosclerosis","volume":"68","author":"Fatah","year":"1992","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.bbrc.2010.03.095_bib13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1161\/01.ATV.19.1.67","article-title":"Relationship between plasma fibrinogen and coronary heart disease in women","volume":"19","author":"Eriksson","year":"1999","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.bbrc.2010.03.095_bib14","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s001250050607","article-title":"Altered properties of the fibrin gel structure in patients with IDDM","volume":"39","author":"J\u00f6rneskog","year":"1996","journal-title":"Diabetologia"},{"key":"10.1016\/j.bbrc.2010.03.095_bib15","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1046\/j.1538-7836.2003.00301.x","article-title":"Increased plasma fibrin gel porosity in patients with Type I diabetes during continuous subcutaneous insulin infusion","volume":"1","author":"J\u00f6rneskog","year":"2003","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.bbrc.2010.03.095_bib16","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1016\/j.thromres.2009.10.006","article-title":"A multicolor flow cytometric assay for measurement of platelet-derived microparticles","volume":"125","author":"Mobarrez","year":"2010","journal-title":"Thromb. Res."},{"key":"10.1016\/j.bbrc.2010.03.095_bib17","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.thromres.2005.02.007","article-title":"Marked increase of fibrin gel permeability with very low dose ASA treatment","volume":"116","author":"Antovic","year":"2005","journal-title":"Thromb. Res."},{"key":"10.1016\/j.bbrc.2010.03.095_bib18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/FJC.0b013e3181953e0f","article-title":"Effects of acetylsalicylic acid on increase of fibrin network porosity and the consequent upregulation of fibrinolysis","volume":"53","author":"He","year":"2009","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.bbrc.2010.03.095_bib19","article-title":"bivaluridin","volume":"103","author":"He","year":"2010","journal-title":"and lepirudin) and the indirect Xa inhibitor (danaparoid) increase fibrin network porosity. Thromb. Haemost."},{"key":"10.1016\/j.bbrc.2010.03.095_bib20","doi-asserted-by":"crossref","first-page":"7937","DOI":"10.1073\/pnas.90.17.7937","article-title":"Mutations of von Willebrand factor gene in families with von Willebrand disease in the Aland Islands","volume":"90","author":"Zhang","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbrc.2010.03.095_bib21","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/BF00191794","article-title":"Effects of the mutant von Willebrand factor gene in von Willebrand disease","volume":"96","author":"Zhang","year":"1995","journal-title":"Hum. Genet."},{"key":"10.1016\/j.bbrc.2010.03.095_bib22","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/0049-3848(76)90209-7","article-title":"On the characterization of acquired inhibitors to ristocetin induced platelet aggregation found in patients with von Willebrand\u2019s disease","volume":"9","author":"Egberg","year":"1976","journal-title":"Thromb. Res."},{"key":"10.1016\/j.bbrc.2010.03.095_bib23","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0049-3848(83)90407-3","article-title":"Evidence for a rapid inhibitor to tissue plasminogen activator in plasma","volume":"31","author":"Chmielewska","year":"1983","journal-title":"Thromb. Res."},{"key":"10.1016\/j.bbrc.2010.03.095_bib24","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0889-8588(05)70136-2","article-title":"The fibrinolytic system. Basic principles and links to venous and arterial thrombosis","volume":"14","author":"Wiman","year":"2000","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.bbrc.2010.03.095_bib25","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJM198512193132501","article-title":"Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction","volume":"313","author":"Hamsten","year":"1985","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2010.03.095_bib26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0140-6736(87)93050-9","article-title":"Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction","volume":"ii","author":"Hamsten","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.bbrc.2010.03.095_bib27","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1073\/pnas.92.6.1851","article-title":"Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction","volume":"92","author":"Eriksson","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbrc.2010.03.095_bib28","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1161\/01.ATV.20.8.2019","article-title":"Plasma levels of tissue plasminogen activator\/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study","volume":"20","author":"Wiman","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.bbrc.2010.03.095_bib29","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1055\/s-0037-1613409","article-title":"Stockholm Heart Epidemiology Program. PAI-1 level and the PAI-1 4G\/5G polymorphism in relation to risk of non-fatal myocardial infarction: results from the Stockholm Heart Epidemiology Program (SHEEP)","volume":"89","author":"Leander","year":"2003","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.bbrc.2010.03.095_bib30","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.thromres.2004.12.007","article-title":"The complex between t-PA and PAI-1: risk factor for myocardial infarction as studied in the SHEEP project","volume":"116","author":"Nordenhem","year":"2005","journal-title":"Thromb. Res."},{"key":"10.1016\/j.bbrc.2010.03.095_bib31","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1160\/TH06-07-0370","article-title":"A global assay of haemostasis which uses recombinant tissue factor and tissue-type plasminogen activator to measure the rate of fibrin formation and fibrin degradation in plasma","volume":"98","author":"He","year":"2007","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.bbrc.2010.03.095_bib32","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1161\/01.ATV.16.11.1333","article-title":"In vivo demonstration that large postprandial triglyceride-rich lipoproteins activate coagulation factor VII through the intrinsic coagulation pathway","volume":"16","author":"Silveira","year":"1996","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.bbrc.2010.03.095_bib33","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/00001721-199512000-00002","article-title":"Increased blood flow resistance in placental circulation and levels of plasminogen activator inhibitors types 1 and 2 in severe preeclampsia","volume":"6","author":"He","year":"1995","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.bbrc.2010.03.095_bib34","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/0049-3848(86)90024-1","article-title":"Activators and inhibitors of coagulation and fibrinolysis in patients with prostatic cancer treated with oestrogen or orchidectomy","volume":"44","author":"Henriksson","year":"1986","journal-title":"Thromb. Res."},{"key":"10.1016\/j.bbrc.2010.03.095_bib35","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0049-3848(88)90364-7","article-title":"Changes in blood coagulation and fibrinolysis in patients on different treatment regimens for prostatic cancer. Predictors for cardiovascular complications?","volume":"49","author":"Blomb\u00e4ck","year":"1988","journal-title":"Thromb. Res."},{"key":"10.1016\/j.bbrc.2010.03.095_bib36","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0268-9499(88)90372-4","article-title":"Effects of plasma kallikrein infusions into pigs on haemodynamic and haemostatic variables","volume":"2","author":"Egberg","year":"1988","journal-title":"Fibrinolysis"},{"key":"10.1016\/j.bbrc.2010.03.095_bib37","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0268-9499(88)90373-6","article-title":"Effects of plasma kallikrein and bradykinin infusions into pigs on plasma fibrinolytic variables and urinary excretion of thromboxane and prostacyclin metabolites","volume":"2","author":"Egberg","year":"1988","journal-title":"Fibrinolysis"},{"key":"10.1016\/j.bbrc.2010.03.095_bib38","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0002-9343(98)00060-6","article-title":"Duration of Anticoagulation Trial Study Group. The predictive value of anticardiolipin antibodies in patients with venous thromboembolism","volume":"104","author":"Schulman","year":"1998","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bbrc.2010.03.095_bib39","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.cell.2009.11.001","article-title":"Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo","volume":"139","author":"M\u00fcller","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2010.03.095_bib40","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1002\/jgm.510","article-title":"Adding functional entities to plasmids","volume":"6","author":"Svahn","year":"2004","journal-title":"J. Gene Med."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X10005462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X10005462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T06:42:10Z","timestamp":1559112130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X10005462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["S0006291X10005462"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2010.03.095","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}